Report Highlights
The Europe Rare Disease Genetic Testing Market Expected to Reach $4.17 Billion by 2033
Introduction to Europe Rare Disease Genetic Testing Market
The Europe rare disease genetic testing market was valued at $1.16 billion in 2023 and is anticipated to reach $4.17 billion by 2033, witnessing a CAGR of 13.60% during the forecast period 2023-2033. The market for genetic testing in rare diseases has experienced notable growth, driven by a rising need for early identification of such conditions. The growing occurrence of rare diseases has been a pivotal factor in this growth trajectory. Moreover, there's a heightened acknowledgment and focus on early detection and prevention, particularly among pediatric populations worldwide, which is anticipated to further drive market growth.
Market Introduction
The Europe rare disease genetic testing market in Europe is witnessing substantial growth driven by several factors. Increasing awareness and advancements in genetic testing technologies have propelled demand for early detection and diagnosis of rare diseases across the continent. Additionally, the rising prevalence of rare diseases in European populations has contributed significantly to market growth. Moreover, there's a growing emphasis on early intervention and personalized medicine, further boosting the adoption of genetic testing for rare diseases. Regulatory initiatives and healthcare policies promoting accessibility to genetic testing services also play a crucial role in market development. As healthcare systems in Europe prioritize precision medicine and improved patient outcomes, the rare disease genetic testing market is poised for continued growth, offering opportunities for innovation and collaboration among stakeholders in the healthcare sector.
Market Segmentation:
Segmentation 1: by Disease Type
- Gastroenterology Disease
- Endocrine and Metabolism Disease
- Cardiovascular Disease
- Neurology Disease
- Hematology and Oncology Disease
- Dermatology Disease
- Other Diseases
Segmentation 2: by Technology
- Sanger Sequencing
- PCR
- NGS
- Microarrays
- Others (Targeted Cytogenetics, Karyotyping, and FISH)
Segmentation 3: by Country
- Germany
- U.K.
- France
- Italy
- Russia
- Spain
- Rest-of-Europe
Report Synopsis
| Report Metrics | Details |
| Base year considered | 2023 |
| Forecast period considered | 2023-2033 |
| Base year market size | $1.16 Billion in 2023 |
| Market size forecast | $4.17 Billion by 2033 |
| Growth rate | 13.60% |
| Units considered | $ Billion |
| Segments covered | By Disease Type, By Technology, By Country |
| Industry covered | BIS Healthcare |
| Regions covered | Europe |
| Countries covered | Germany, U.K., France, Italy, Russia, Spain, Rest-of-Europe |
| Companies studied |
|
How Can This Report Add Value to an Organization?
Product/Innovation Strategy: The rare disease genetic testing market has been extensively segmented based on various categories, such as disease type, technology, and country. This can help readers understand which segments account for the largest share and which are well-positioned to grow in the coming years.
Competitive Strategy: The rare disease genetic testing market has numerous established players paving their way into providing tests, panels, and assays in the market. Key players in the rare disease genetic testing market analyzed and profiled in the study involve established players offering various disease-specific panels and multiplex instruments.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Some of the prominent names established in this market are:
- CENTOGENE N.V.
- Eurofins Scientific SE
- QIAGEN N.V.
This report will be delivered in 1-5 working days.
BIS Research is a global B2B market intelligence and advisory firm focusing on those emerging technological trends which are likely to disrupt the dynamics of the market.
With over 150 market research reports published annually, BIS Research focuses on high technology verticals such as 3D Printing, Advanced Materials and Chemicals, Aerospace and Defense, Automotive, Healthcare, Electronics and Semiconductors, Robotics and UAV, and other emerging technologies.
Our in-depth market intelligence reports focus on the market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More